top of page
Suche

Lancet Oncol. 2022 May

  • christineeulenburg
  • 1. Jan. 2023
  • 1 Min. Lesezeit

De-escalated neoadjuvant pertuzumab plus trastuzumab therapy with or without weekly paclitaxel in HER2-positive, hormone receptor-negative, early breast cancer (WSG-ADAPT-HER2+/HR-): survival outcomes from a multicentre, open-label, randomised, phase 2 trial

Ulrike Nitz et al.

PMID: 35405088 Clinical Trial.

 
 
 

Aktuelle Beiträge

Alle ansehen
JAMA. 2023 Oct

Adherence to CPAP Treatment and the Risk of Recurrent Cardiovascular Events: A Meta-Analysis. Sánchez-de-la-Torre M, Gracia-Lavedan E,...

 
 
 
JAMA Oncol. 2023 Jul

Efficacy of Endocrine Therapy Plus Trastuzumab and Pertuzumab vs De-escalated Chemotherapy in Patients with Hormone...

 
 
 
J Clin Oncol. 2023 Aug

De-Escalated Neoadjuvant Trastuzumab-Emtansine With or Without Endocrine Therapy Versus Trastuzumab With Endocrine Therapy in HR+/HER2+...

 
 
 

Comentarios

bottom of page